Unicycive Therapeutics (UNCY)
(Delayed Data from NSDQ)
$0.34 USD
-0.01 (-1.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.35 +0.01 (3.61%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Unicycive Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 0 | 17 | 0 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 2 | 2 | 0 | 0 |
Total Current Assets | 13 | 3 | 18 | 0 | 0 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 14 | 3 | 19 | 0 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 2 | 0 |
Accounts Payable | 1 | 1 | 1 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 2 | 1 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 18 | 3 | 2 | 3 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18 | 3 | 2 | 3 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 61 | 34 | 32 | 3 | 3 |
Retained Earnings | -65 | -34 | -16 | -6 | -4 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -4 | 0 | 16 | -3 | -1 |
Total Liabilities & Shareholder's Equity | 14 | 3 | 19 | 0 | 0 |
Total Common Equity | -4 | 0 | 16 | -3 | -1 |
Shares Outstanding | 34.70 | 15.00 | 14.90 | NA | NA |
Book Value Per Share | -0.11 | -0.03 | 1.11 | 0.00 | 0.00 |
Fiscal Year End for Unicycive Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 42 | 49 | 10 | 14 | 19 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 4 | 4 | 3 |
Total Current Assets | 44 | 52 | 13 | 19 | 22 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 45 | 52 | 14 | 19 | 23 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 4 | 3 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 25 | 13 | 12 | 13 |
Total Current Liabilities | 13 | 30 | 18 | 15 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 46 | 46 | 0 | 0 | 0 |
Total Liabilities | 60 | 77 | 18 | 16 | 16 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 26 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 61 | 61 | 61 | 60 | 33 |
Retained Earnings | -76 | -86 | -65 | -57 | -52 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -15 | -24 | -4 | 3 | 7 |
Total Liabilities & Shareholder's Equity | 45 | 52 | 14 | 19 | 23 |
Total Common Equity | -15 | -24 | -4 | 3 | -19 |
Shares Outstanding | 43.50 | 37.60 | 34.70 | 34.70 | 15.20 |
Book Value Per Share | -0.34 | -0.65 | -0.11 | 0.10 | -1.27 |